Baxter, one of the larger firms in the dialysis business (but nowhere that powerful in the clinic business), made an announcement that it is planning to spin off its renal care and acute therapies unit into another public company. It expects to complete the divestiture in 2024 or so.
Continue reading Memories- with an averted nightmare
More than 35 years ago, I developed a new dialysate system, one that was more physiological for patients. And, we began selling our product all over America- and then the world.
Continue reading Car 54, where are you?
An apology. This was supposed to be another piece in my stem cell update series. But, somehow, it got moved weeks ahead in the queue. (We discussed the technology on 13 June, 12 June, and 11 June.) And, now, again, today.)
Continue reading Even the Feds will fail?
Yesterday, we spoke about the proliferation of stem cell therapy (sic) centers in America. After all, these clinics are not regulated by the Feds, which leaves the business open to every single snake oil salesman and saleswomen. Most of these slimeballs promise to extract vital stem cells from the fat in our bodies (I don’t know about you, but I have a lot of those to donate) to create medical miracles.
Continue reading R-r-regulation? Hmm. Not really.
